Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To collect the efficacy and safety information in subjects who have been treated with Zyvox (linezolid) for vancomycin resistance Enterococcus faecium infection for their appropriate use in daily practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Linezolid; Vancomycin

Criteria

Inclusion Criteria:

• Subject to whom Zyvox (linezolid) was administered.

• Infected subject with Vancomycin resistance Enterococcus faecium.

Exclusion Criteria:

• Infected subject with MRSA and other organism.